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Oxidation resistance gene 1 (OXR1) protects cells
against oxidative stress. We find that male mice
with brain-specific isoform A knockout (Oxr1A/)
develop fatty liver. RNA sequencing of male
Oxr1A/ liver indicates decreased growth hormone
(GH) signaling, which is known to affect liver meta-
bolism. Indeed, Gh expression is reduced in male
mice Oxr1A/ pituitary gland and in rat Oxr1A/
pituitary adenoma cell-line GH3. Oxr1A/ male
mice show reduced fasting-blood GH levels. Pull-
down and proximity ligation assays reveal that
OXR1A is associated with arginine methyl trans-
ferase PRMT5. OXR1A-depleted GH3 cells show
reduced symmetrical dimethylation of histone H3
arginine 2 (H3R2me2s), a product of PRMT5 cata-
lyzed methylation, and chromatin immunoprecipita-
tion (ChIP) of H3R2me2s shows reduced Gh
promoter enrichment. Finally, we demonstrate with
purified proteins that OXR1A stimulates PRMT5/
MEP50-catalyzed H3R2me2s. Our data suggest
that OXR1A is a coactivator of PRMT5, regulating
histone argininemethylation and therebyGHproduc-
tion within the pituitary gland.
INTRODUCTION
The oxidation resistance gene 1 (OXR1) is highly conserved in
eukaryotes and was originally identified as an anti-oxidation
gene in yeast (Elliott and Volkert, 2004; Fischer et al., 2001).
This role has been confirmed in several other species, including
humans (Yang et al., 2015; Yang et al., 2014), mice (Finelli et al.,Cell R
This is an open access article under the CC BY-N2015; Liu et al., 2015; Oliver et al., 2011), worms (Sanada et al.,
2014), and insects (Jaramillo-Gutierrez et al., 2010). Mice lacking
all OXR1 isoforms displayed severe neurodegeneration and died
early after birth (Jaramillo-Gutierrez et al., 2010; Oliver et al.,
2011). Recently, studies in mice showed that overexpression
of OXR1 in neurons extends the survival of an amyotrophic
lateral sclerosis model, perhaps reflecting the relation of OXR1
to oxidative stress (Liu et al., 2015). Studies in C. elegans reveal
thatOXR1 has a role in regulating aging andmaintaining a normal
lifespan (Sanada et al., 2014), but its molecular function and the
roles in physiology and pathophysiology are still incompletely
understood.
Brain pathology has been shown to induce systemicmetabolic
alterations, such as those contributing to metabolic syndromes
and liver steatosis, potentially involving disturbed signaling of
neurotransmitters and hormones including pituitary-gland-
derived mediators (e.g., growth hormone [GH] and thyroid
stimulating hormone [TSH]) (Auer et al., 2016; Brown et al.,
1997; Chishima et al., 2017; Ichikawa et al., 2007; Sos et al.,
2011). The regulation and operating molecules of these path-
ways, including the brain-liver axis, however, are far from clear.
Similar to humans (Elliott and Volkert, 2004; Yang et al., 2014),
mice express at least four differentOXR1 isoforms (Fischer et al.,
2001). Although all tissues appear to express the shortest iso-
form, Oxr1D, the longest isoform (Oxr1A) in mice is expressed
only in the brain. Isoform B is not expressed in the brain but in
other tissues, such as the liver and the heart. We have recently
generated a brain-specific Oxr1A knockout (KO) mouse model.
Based on the putative role of OXR1 as a sensor of cellular oxida-
tive stress (Yang et al., 2014, 2015) and the possible role of these
processes in the regulation of neuroendocrine responses, we
used OXR1A-deficient mice and Oxr1A knockdown and KO
cell lines to study the brain-liver axis with a focus on neuroendo-
crine regulation. We found that Oxr1A/ mice developed liver
steatosis, associated with reduced GH levels and indicationseports 30, 4165–4178, March 24, 2020 ª 2020 The Authors. 4165
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of decreased GH receptor signaling in the liver. Our results
further suggest that OXR1A acts as a coactivator of protein argi-
ninemethyltransferase 5 (PRMT5), increasing symmetrical dime-
thylation of histone H3 arginine 2 at the Gh promoter in the
pituitary gland and, consequently, increases Gh transcription.
These data reveal a role for OXR1A in oxidative stress signaling
as a regulator of protein arginine methylation, which promotes
Gh expression in the pituitary gland and thereby influences liver
lipid metabolism.
RESULTS
Construction of a Brain-Specific Oxr1A/ Mouse Strain
By searching the mice genome databases and comparing them
with human OXR1, we identified at least six Oxr1 transcript var-
iants that can be classified into A, B1–B4, and D isoforms
(Figures 1A and S1A). Each isoform has one or several unique
exons at the 50 end. The longest isoform, Oxr1A (GeneBank:
NM_001130166), consists of 17 exons with three unique exons
(exons 1–3).
A brain-specific Oxr1A KO mouse strain (Oxr1A/) was
generated by the gene-trap approach (Figures 1A and S1B).
The KO mice were viable and produced offspring normally
(Mendelian distribution). The KO genotype was verified by PCR
(Figure S1B). Further, western blot analysis with an OXR1A-spe-
cific antibody (OXR1 Ab1, made by our laboratory) showed that
the OXR1A protein was lacking in theOxr1A/ brain (Figure 1B).
Our previous studies demonstrated that human OXR1A is ex-
pressed only in the brain (Yang et al., 2014). Similarly, mouse
Oxr1A also appears to be expressed in the brain, including the
pituitary gland in wild-type (WT) (Figure S1C) but not in the liver
(Figure 1B). Western blot analysis of the same brain and liver tis-
sues samples as above, using an OXR1 antibody (OXR1 Ab2,
Bethyl Laboratories, Inc.), which recognized an epitopemapping
to exon 8 in both isoforms (A and B), confirmed that OXR1A is
lacking in the Oxr1A/ brain. In addition, livers of WT and
Oxr1/ mice showed the same levels of OXR1B expression,
demonstrating that knocking outOxr1A did not affect the protein
expression of OXR1B in the liver (Figure 1B). In agreement with
the protein data, by using Oxr1A-specific primers spanning
exons 2–3 (Figure S1A), qPCR analysis showed that Oxr1A
mRNA was significantly expressed only in the brain of WT, but
not in the brain of KO,mice or in the liver or other tissues (i.e., kid-
ney, spleen, testis, lung, and thymus) of both WT and KO mice
(Figure S1D). Thus, the Oxr1A isoform is selectively expressed
in the brain and in the pituitary gland, but not in the liver or any
other tissues analyzed.
OXR1A/ Mice Display Liver Steatosis
Based on the relationship between the brain and systemic meta-
bolic pathways, including the brain-liver axis, we hypothesized
that deficiency in Oxr1A, with expression restricted to the brain,
could induce systemic metabolic disturbances, such as liver
steatosis. Indeed, histological examination of the liver of 12-
month-old mice showed markedly enhanced fat accumulation
in the male Oxr1A KO as compared with WT mice (Figure 1C).
Further characterization of these mice showed increased hepat-
ic triglyceride levels, but not cholesterol levels, in Oxr1A/, as4166 Cell Reports 30, 4165–4178, March 24, 2020compared with WT, mice, with the most pronounced changes
in the male mice (Figure 1D). These findings demonstrate the
development of liver steatosis in Oxr1A/ mice. Twelve-
month-old, male KO mice, but not the female, also showed
altered oral glucose tolerance, indicating decreased insulin
sensitivity (Figure 1E). Moreover, 12-month-old male and female
Oxr1A KO mice showed a tendency toward increased body
weight as compared with WT mice (Figure 1F). In contrast, the
body weight was significantly reduced at day 3, 8, and 9 in young
Oxr1A/ mice. In addition, Oxr1A/ mice showed a tendency
toward reduced body weight gain in the first 3 weeks after birth
(Figure S1E). All together, these data suggest that OXR1A is
involved in stimulating body growth, and the increase in body
weight in 12-month-old KO mice might reflect secondary phe-
nomenon related to disturbed metabolism. To further examine
the growth phenotype and liver steatosis, food intake was moni-
tored (Figure S1F), and no differences were observed between
the genotypes. To test whether the liver steatosis phenotype
was associated with alterations in fatty acid (FA) oxidation and
synthesis, we examined the hepatic activity of three enzymes
involved in FA oxidation (i.e., carnitine palmitoyl transferase I
[CPT-1], CPT-2, and fatty acid oxidase [FAO]), showing no differ-
ences between the two genotypes (Figures S1G–S1I). In addi-
tion, even when testing sensitivity to the natural key inhibitor of
CPT-1, malonyl-coenzyme A (CoA), we found no differences
between the two genotypes (Figure S1I), underscoring that there
are no differences in hepatic mitochondrial beta-oxidation of FA
betweenWT andOxr1A/mice. These findings suggest that the
effect of Oxr1A KO on liver steatosis is mediated through other
mechanisms or through other FA metabolic proteins.
Differentially Expressed Genes (DEGs) ofOxr1A/Male
Liver Are Enriched in Hormone Response, Fatty Liver
Metabolism, and Immune Response
To provide mechanistic insight into how the absence of OXR1A
in the brain triggers fatty liver, we investigated the transcription
profile and compared the DEGs in the liver of 12-month-old
mice. The RNA sequencing (RNA-seq) data of mice liver consist
of four groups with three biological replicates in each group: WT
males, Oxr1A/ males, WT females, and Oxr1A/ females.
Principal-component analysis (PCA) showed that the difference
in the transcriptomes between Oxr1A/ and WT mice was
much larger in males than it was in females (Figure S2A). We
identified 724 DEGs in males, and most of them were upregu-
lated in Oxr1A/ mice in comparison to WT mice (652 genes
upregulated and 72 genes downregulated). In contrast, only
169 genes (64 upregulated and 105 downregulated) were differ-
entially expressed in the female of Oxr1A/ mice (Figure 2A;
Tables S1 and S2). In total, 49 genes are commonly regulated
by OXR1A in both genders, whereas a large number of DEGs
(675 genes) were uniquely regulated in males (Figure S2B). To
verify the liver RNA-seq data, we measured the mRNA level of
DEGs by RT-PCR. In agreement with the RNA-seq, all the tested
genes showed significant differences in transcription level be-
tween WT and OXR1A-deficient mice (Figure S2H). Gene
Ontology (GO) analysis showed that, in male mice, a subset of
DEGs (22 genes) is enriched in FA metabolism (Figures 2B and
2C), whereas the other three subsets of genes are enriched in
Figure 1. OXR1A Deficiency Causes Fatty Liver in Male Mice
(A)Oxr1A knockout (KO) generated by the gene trap approach. A DNA fragment that included the neomycin gene (NEO) and a long terminal repeat sequence was
inserted into the intron between exons 1 and 2 to disrupt Oxr1 transcription.
(B) Verification of Oxr1A KO by western blot analysis, using an antibody (Ab1) that specifically recognizes OXR1A or an antibody (Ab2) that recognizes both
OXR1A and B proteins. Cytochrome c (Cyto C) was used as the loading control.
(C) Hematoxylin and eosin stains of the liver of 12-month-old mice.
(D) Triglyceride (TG) and cholesterol (CHOL) levels in the liver of 12-month-oldOxr1A/ andWTmice. n = 8 (WT, male), 13 (Oxr1A/, male), 5 (WT, female), and 9
(Oxr1A/, female).
(E) Oral glucose tolerance test of 12-month-old mice. n = 7 (WT, male), 11 (Oxr1A/, male), 2 (WT, female), and 5 (Oxr1A/, female).
(F) Body weight of mice.
Error bars represent mean ± SD. *p < 0.05, **p < 0.01.
See Figure S1.
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Figure 2. Dysregulation of the Transcriptome in the Liver of OXR1A-Deficient Male Mice
(A) Total numbers of differentially expressed genes (DEGs) in the liver of 12-month-old Oxr1A/ mice as compared with WT.
(B) GO biological process enrichment analysis of DEGs in the livers of 12-month-old Oxr1A/ mice as compared with WT.
(C) Heatmap for a subset of DEGs enriched in fatty acid metabolism and transport in 12-month-old Oxr1A/ male mice as compared with WT controls.
(D) Schematic diagram of GH regulation of hepatocyte transcriptome via the GHR-STAT5 axis. The Gh expression is regulated by Pit1 in the pituitary gland and
transported to hepatocytes via blood circulation where it binds to the GH receptor (GHR) and induces JAK2-mediated STAT5 phosphorylation. Phosphorylated
STAT5 translocates to the nucleus and activates the transcription of its target genes. Inactivation or depletion of GHR or STAT5 results in STAT1 activation (arrow
with dash line in red).
(E) Transcription levels of GHR-dependent STAT5- and STAT1-targeted genes in the livers of 12-month-oldmalemice. ThemRNAwasmeasured by qPCR. n = 3.
Error bars represent mean ± SD. *p < 0.05.
See Figure S2 and Tables S1, S2, S3, and S4.
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the hormone response (24 genes), immune response (164
genes), and apoptosis (106 genes) (Figures 2B and S2E–S2G).
The total number of DEGs and enrichment in several steatosis-
related processes were much less pronounced in females than
they were in males (Figure 2B). GO molecular-function analysis
revealed that the major classes of DEGs belonged to binding
and catalytic activity (Figure S2C). Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway-enrichment analysis showed
that the pathogenesis of this fatty liver disease also involves im-
mune activation, enhanced apoptosis, and abnormal lipid meta-
bolism (Figure S2D). For instance, we observed more than a
2-fold increase in expression of Il1b (interleukin-1 beta) in
Oxr1A KO male mice (Figure S2H).
The pituitary gland secretes several hormones of importance
for systemic metabolism, such as GH and TSH. Indeed, both
TSH and, in particular, GH deficiency have been related to liver
steatosis (Auer et al., 2016; Brown et al., 1997; Chishima et al.,
2017; Ichikawa et al., 2007; Sos et al., 2011).Oxr1A is expressed
in the pituitary gland (Figure S1C). The murine major urinary pro-
teins (Mups) are encoded by at least 21 genes, namedMup1–21.
The liver Mups are regulated by hormones, including GH,
thyroxin, and testosterone. As such, Mups serve as biomarkers
for pituitary-gland-related hormones (Knopf et al., 1983). RNA-
seq showed that 13 Mup genes in male Oxr1A/ mice were
significantly downregulated, especially those that are typical
for male mice (e.g., Mup20, Mup7, and Mup11) (Figure S2I). In
females, 9 Mup genes were also downregulated in Oxr1A/
mice, including those that are typical for females (e.g., Mup4
and Mup13) (Figure S2I; Table S1).
The Liver Transcriptome of the GHR-STAT5 Axis-
Deficient Male Mice Resembles That of Oxr1A/ Male
Mice
Based on our data, we speculated that the liver steatosis in
Oxr1A/ mice could be related to downregulation of GH secre-
tions from the pituitary gland. In liver, GH binds to the GH recep-
tor (GHR) in hepatocytes, thereby activating transcription factor
STAT5 via JAK2-mediated phosphorylation (Barclay et al., 2011;
Zhang et al., 2012) (Figure 2D). Previous studies have demon-
strated that most GH-regulated hepatic genes are subject to
STAT5 control (Barclay et al., 2010). The kinetics of GHR-JAK-
STAT activation, in particular, the activation of STAT5, is critically
dependent on the pulse pattern of the GH secretion (Choi and
Waxman, 2000; Gebert et al., 1997). Indeed, our RNA-seq data
showed that 68 of the total 775 DEGs were targets of STAT5 in
Oxr1A/ male liver, indicating that GH-mediated regulation of
JAK2-STAT5 activation was altered, which may suggest that
the pulsatile secretion pattern of GH is attenuated in OXR1A-
deficient male mice. A KEGG pathway enrichment analysis
further confirmed that the Jak-STAT pathway was significantly
enriched (Table S3). Comparison of the transcriptome of
Oxr1A/ male livers with the transcriptomes of the livers of
the Ghr-391 mutant, Ghr/ (Barclay et al., 2011), Pit1 mutant,
or Prop1- and Ghrhr-mutant mice (Boylston et al., 2006;
Swindell, 2007), showed many common DEGs (Table S4). For
example, the Oxr1A/ mice showed reduced expression of
STAT5 target genes Igfbp2 and Mup3 (Table S1; Figure 2E).
Moreover, lack of STAT5 activation leads to increasedStat1 transcription and activation (protein expression and
phosphorylation) (Barclay et al., 2011). This is consistent with
our findings demonstrating increased expression of Stat1 and
its target genes, including Cd36 and Vldlr (very low density lipo-
protein receptor) in Oxr1A / liver, both of major importance for
lipid metabolism and transport within the liver (Figure 2E; Tables
S1 and S3). These overlaps in the liver gene-expression profiles
further support the involvement of GH deficiency in the induction
of liver steatosis in Oxr1A/ male mice.
Reduced GH Level in Blood of Oxr1A/ Male Mice
Our data so far, and in particular the downregulation of 13 Mup
genes in male Oxr1A/ mice, could suggest the involvement
of altered pituitary hormones, such as GH in the liver steatosis
seen in Oxr1A / mice. To further examine our hypothesis, we
tested the influence of OXR1A on blood levels of pituitary-
derived hormones that could be related to liver steatosis, such
asGH, FSH (follicle-stimulating hormone), ACTH (adrenocortico-
tropic hormone), and TSH. We first measured blood GH levels
after 4 h of fasting as a standard test for de-masking GH defi-
ciency. Although fasting dramatically induced GH levels in the
blood in 6-month-old WT mice with an average of a 20-fold
increase, that result was not seen in Oxr1A/ male mice
(Figure 3A). Further, 12-month-old mice showed no significant
differences in ACTH, FSH, and TSH levels in blood between
the two genotypes (Figure S3A). These data support OXR1A as
regulating GH, but not regulating ACTH, FSH, and TSH. IGF-1
(insulin-like growth factor 1) is a well-characterized protein that
can be positively regulated by GH. However, the blood IGF-1
level is not reduced in the Oxr1A KO male mice as compared
with the WT mice (Figure S3B).
Gene Expressions of Gh in the Pituitary Gland Are
Reduced in Oxr1A/ Male Mice
Our findings so far suggest that GH deficiency could mediate the
liver phenotype inOxr1A/ mice. Therefore, we next performed
a series of experiments to examine how OXR1A could regulate
GH. Western blot analysis showed that OXR1A was indeed
expressed in the pituitary gland, as well as in the whole brain
of WT, but not Oxr1A/, mice (Figures 1B and S1C). Next, we
examined the gene expression of Gh (Figure 3B) in pituitary
glands of 6-month-old Oxr1A/ and WT mice. Although the
gene-expression levels of Gh were spread over a large range
in the pituitary gland of 6-month-old WT mice, showing a
5-fold difference between the lowest and the highest value, Gh
expression in the Oxr1A/ pituitary gland showed no variation
because all mice displayed values similar to the lowest values
in WT mice. Thus, it appears that WT mice express Gh over a
dynamic range in 6-month-old pituitary glands, in support of a
pulsatile expression pattern, whereas that regulation is absent
in the OXR1A-deficient mice. In the pituitary glands of
12-month-old mice, expression of Gh declined to a level below
the level at 6 months in both WT and Oxr1/ mice (Figure 3B),
indicating that the age-related drop in Gh expression acceler-
ated in OXR1A-deficient mice. In fact, the lack of the pulsatile
pattern, as well as an impaired response to fasting, is a more reli-
able feature of GH deficiency than the actual level. In contrast to
Gh, transcript levels of Tshb and Pomc, both with potentialCell Reports 30, 4165–4178, March 24, 2020 4169
Figure 3. Hormone Expression and Secretion
Are Reduced in the Pituitary and Blood,
Respectively, in Oxr1A/ Male Mice
(A) The plasma GH protein was measured by ELISA
kit in 6-month-old male mice after fasting.
(B) The Gh expression in the pituitary of male mice
was measured by qPCR. n = 4–6.
(C) Immune staining of OXR1A and GH protein in
primary cell cultures derived from the pituitary gland
of mice. The numbers of GH-positive (GH+), OXR1A-
positive (OXR1+), and double-positive (GH+ OXR1A+)
cells were quantified (right panels). At least five fields
were counted from each group. #The cell type was
not observed.
Error bars represent mean ±SD. *p < 0.05, **p < 0.01.
See Figure S3.relevance for the development of fatty liver, as well as the
expressions of several hormone receptors (Ghrhr, Sstr, Igf1r,
and Trhr) were not differentially regulated inOxr1A KOmice (Fig-
ure S3C). Prolactin (Prl), however, showed a tendency toward
downregulation in 6-month-old Oxr1A/ mice (Figure S6A).OXR1A Showed the Highest Expression in Primary GH-
Producing Pituitary Gland Cells Derived from Male, but
Not Female, Mice
To gain further insight in the function of OXR1 in the regulation of
GH expression, we generated primary cell cultures derived from
the anterior lobe of the murine pituitary gland. Fluorescence mi-
croscopy with anti-GH showed that a minor sub-population of
the cellswasGHpositive (Figure 3C).Notably, staining of cultures
derived frommalemice showed that OXR1Awas enriched inGH-
producing cells. In female-derived cultures,OXR1A-positive cells
showed no significant GH staining, whereas GH-positive cells
lacked OXR1 staining (Figure 3C). Thus, it appears that OXR1A-
mediated regulation ofGh expression is sex dependent, support-
ing the theory that dysregulation of hepaticGH signaling and fatty
liver occurs predominantly in male Oxr1A/ mice.GH-Producing Cells Co-expressed OXR1A in Male
Pituitary Gland
The overall size of the pituitary glands from adult WT and
Oxr1A/ male mice was similar (Figure S3E). To evaluate the
histological characteristics of the pituitary glands in more detail,4170 Cell Reports 30, 4165–4178, March 24, 2020we performed histological analysis on the
whole pituitary gland from adult male
mice. H&E staining (Figure S3F) showed
no obvious differences in morphology be-
tween the KO and control mice. Both geno-
types displayed similar well-developed
structures consisting of three lobes: ante-
rior, posterior, and intermediate pituitary.
GH-producing cells made up the main
part of the anterior lobe.
Similar to the results from the primary
cultured pituitary cells, staining of tissue
sections with an anti-OXR1A antibodyshowed that OXR1A was more enriched in GH-producing cells
in males than it was in females. About 50% (51/100) of GH-pro-
ducing cells co-expressed OXR1A in the male pituitary, whereas
only 25% (22/89) in the female (Figure S3G).
To explore the location of OXR1A in relation to other hormone-
producing cells in the pituitary gland, we performed a series of
immunofluorescence staining with anterior pituitary glands from
both adult male and female WT mice. We found OXR1A co-ex-
pressed with part of the LH- and TSH-producing cells in both
adult male and female mice, with part of the PRL-producing cells
in female. There was little co-localization of OXR1 in ACTH- and
FSH-producing cells in bothmale and female mice. (Figure S3H).
PRMT5 Interacts with OXR1 in Cell Extracts
To reveal the molecular function of OXR1A underlying regulation
ofGh expression, we searched for protein interaction partners of
OXR1. We generated U2OS cell lines with stable expression of
human OXR1A-GFP or GFP alone that were used in immunopre-
cipitation (IP) experiments with anti-GFP. The proteins pulled
down from the IP were analyzed by mass spectrometry (MS).
Of particular interest, we found that the protein arginine methyl-
transferase 5 (PRMT5) precipitated together with OXR1A (Table
S5). This IP experiment was repeated three times, and we
detected PRMT5 every time in the pull-down fraction by MS.
Control experiments repeated three times with the GFP protein
alone showed no detectable pull-down of PRMT5.
To further map the domain involved in the interaction with
PRMT5, we performed a similar coimmunoprecipitation (coIP)
Figure 4. OXR1 Interacts with PRMT5 to Promote Gh Expression in Rat Pituitary Cell Line GH3
(A and B) A proximity ligation assay was performed to detect the interaction between OXR1A and PRMT5 (red spots) in GH3 cells with or without siPrmt5 and
siOxr1 knockdown (A) or in WT and Oxr1A/ GH3 cells (B). The nuclei were stained with DAPI. The interaction was detected with both OXR1 and PRMT5
antibodies. OXR1 antibody alone (A) or PRMT alone (B) showed no signal (negative control). The interaction was quantified (right panel) as the percentage of the
signal intensity related to that of the control (siCon) in (A). At least 30 cells were analyzed from each group.
(C) Gh expression was measured in GH3 cells transfected by control siRNA (siCon), siOxr1, or siPrmt5. Three days after siRNA transfection, total RNA was
isolated, and the Gh expression was measured by qPCR. Actin was used as the internal control. n = 4.
(legend continued on next page)
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with U2OS cells overexpressing OXR1D-GFP. Notably, PRMT5
was also identified as one of the OXR1D-binding proteins. The
OXR1D isoform mainly consists of the TLDc domain presented
in all OXR1 isoforms, thus suggesting that the TLDc domain
may facilitate the interaction between OXR1 and PRMT5.
PRMT5 has been shown to form complexes with MEP50 (meth-
ylosome protein 50, encoded by gene WDR77) to catalyze pro-
tein arginine methylation (Antonysamy et al., 2012; Blanc and
Richard, 2017; Stopa et al., 2015). However, MEP50 was not
significantly enriched by coIP in U2OS cells of the overexpres-
sion OXR1A or OXR1D. One possibility is that MEP50 is below
detection level. To increase sensitivity in detecting potential
OXR1 protein partners, we performed targeted MS of coIP pro-
teins. Indeed, we found that some known protein partners of
PRMT5, such as MEP50, ICLN, and WDR5, co-purified with
OXR1A as well as OXR1D, supporting the idea that the core
domain of OXR1 (the TLDc domain) facilitates these protein inter-
actions (Figures S4A–S4G).Verification of the OXR1 and PRMT5 Interaction In Vivo
The PRMT5 has a crucial role in regulation of many intracellular
processes, including transcription by symmetric dimethylation
of arginine on histones H2A, H3, and H4 or non-histone proteins
(Berger, 2008; Burgos et al., 2015; Chen et al., 2017; Chu et al.,
2015; Guo et al., 2010; Jansson et al., 2008; Kim et al., 2014;
Scoumanne et al., 2009; Stopa et al., 2015; Yang and Bedford,
2013). To verify the interaction of endogenous OXR1A with
PRMT5, we performed proximity ligation assays (PLAs) in a rat
pituitary adenoma-derived cell line GH3 (Figures 4A and 4B).
The PLA showed strong signals for OXR1A-PRMT5 interactions
both in cytoplasm and the nucleus in control small interfering
RNA (siRNA)-transfected cells, whereas cells transfected with
siOxr1 and siPrmt5 showed a strong reduction in signal intensity.
There was no detectable signal in PLA control assays using only
one primary antibody (i.e., anti-OXR1A) in control siRNA-trans-
fected cells (Figure 4A). Thus, it appears that, in pituitary cells,
OXR1A interacts with PRMT5. Western blot analysis confirmed
that the GH3 cells transfected with siOxr1 and siPrmt5 showed
reduced expression of the siRNA-targeted proteins (Figure S5A).
Next, we generated GH3 Oxr1A KO cell lines by the CRISPR-
Cas9 approach (Shalem et al., 2014) targeting exon 3 (Oxr1
Ex3). Consistent with the siRNA data above, the PLA interaction
signals between OXR1A and PRMT5 were strong in both the
cytoplasm and the nucleus of WT cells but totally lost in GH3
Oxr1A KO cells (Figure 4B), confirming that isoformOXR1A inter-
acts with PRMT5. These data are clearly demonstrating that
OXR1A and PRMT5 interact both in the nucleus and the
cytoplasm in vivo.(D) Western blot analysis. GH levels in Oxr1A/ cells (Oxr1 Ex3) were calculat
(GAPDH) was used as loading control. n = 3. #Less than a detectable level.
(E) Gene expression of Gh was measured by qPCR. n = 3.
(F) GHgene and protein expressionwere significantly increased in OXR1A-KOGH
the C-terminal TLDc domain (OXR1ADTLDc). Top left: illustration of OXR1A fragm
after plasmids transfection. Right: Gh gene expression was measured by qPCR (
bars represent mean ± SD. **p < 0.01, *p < 0.05.
See Figures S4 and S5 and Tables S5, S6, S7, and S8.
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tary cell cultures showed co-localization between OXR1A and
PRMT5 mainly in the cytoplasm but also in the nucleus (Fig-
ure S5B). Finally, we examined the interaction between purified
recombinant PRMT5 and OXR1A by surface plasmon resonance
(Biacore). We were not able to detect any significant interaction
between purified OXR1A and PRMT5 (data not shown), which
may indicate that the interaction is weak in the absence of pro-
tein partners present in the cell, such as other PRMT5-interacting
partners (i.e., MEP50, ICLN, and WDR5) shown to be present in
pull-down experiments with OXR1A or OXRD (Figure S4A–S4G).
In contrast, histone H3.1 was not enriched by pull-down with
OXR1A or OXR1D (Figure S4H).
In addition to PRMT5, PRMT1 also interacts with Oxr1A/.
PRMT1 functionally catalyzes monomethylation and asymmetric
dimethylation at arginine sites on histones and other proteins.
PLAs using OXR1A and PRMT1 antibodies showed strong sig-
nals in GH3 cells transfected with control siRNA, whereas the
signals were strongly reduced in siOxr1 and siPrmt1 double-
knockdown GH3 cells (Figure S5C). Western analysis confirmed
that siPrmt1 knockdown reduced its protein expression effi-
ciently (Figure S5A). The targeted MS also detected PRMT1 in
the pull-down from OXR1A and OXR1D (Figure S4). Overall,
these data strongly suggest that OXR1A interacts directly with
PRMT1 and PRMT5 within the pituitary gland.
OXR1A and PRMT5 Regulate Gh Expression in Pituitary
Gland Cell Line GH3
To examine the role of OXR1A and PRMT5 in transcriptional
regulation of Gh, we measured the mRNA levels of Gh in the
rat GH3 cell line by qPCR. In RNAi experiments, expression of
Gh was significantly reduced after silencing Oxr1 (targeting all
isoforms) or Prmt5 (Figure 4C). The expression level of Gh was
reduced 60% in Oxr1-silenced cells as compared with control
cells. These data may suggest that the interaction of OXR1
and PRMT5 has a role in transcriptional regulation of Gh. Next,
we used the GH3Oxr1A KO cell line targeting exon 3 to examine
Gh expression.Western analysis showed that theOXR1A protein
was absent in the KO strain (Figure 4D). Notably, GH protein and
Gh gene expression decreased 80% and 90%, respectively, as
compared with WT controls (Figure 4D). Similarly, KO of Oxr1
with guide RNA targeting exon 5 (which is unique for isoform A
and B) or exon 15 (a common exon for all isoforms), also resulted
in reduction in GH protein expression (Figure S5D). Pulsatility
and gender dimorphism in GH secretion is regulated by GHRH
(growth hormone releasing hormone) and SST (somatostatin)
produced in hypothalamus. To explore whether OXR1A affects
GH expression via this axis, we measured gene expression of
Sst and other related regulators Igf1, Igf1r, Ghrh, Sstr, and Trhed relative to that of WT cells. Glyceraldehyde-3-phosphate dehydrogenase
3 cells rescued by full-length humanOXR1A, but not by amutant protein lacking
ents inserted into plasmid pEGFP-N. Bottom left: GH3OXR1AKO cells 2weeks
n = 6), and GH protein expression was measured by western blot (n = 3). Error
(legend on next page)
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in the male hypothalamus (Figure S3D). There were no differ-
ences in those genes between the two genotypes, excluding
the possibility of OXR1-mediated GH expression via cross
talking with hypothalamus regulators.
Forskolin (FSK) induces Gh expression in pituitary glands by
modulating cellular cyclic AMP (cAMP) concentration and acti-
vation of its signaling pathway, including phosphorylation of
CREB, which is a key transcription factor upregulating Pit1
expression. Pit1 is a crucial transcription factor for regulating
GH expression (Monteserin-Garcia et al., 2013; Shepard et al.,
1994). In agreement with previous reports (Cuttler et al., 1993;
Szabo et al., 1990), both Gh and Prl expressions were increased
after treatment with 5 mM of FSK for 3 h. Importantly, FSK-
induced GH was attenuated by Oxr1A knockdown (Figure S5E).
Interestingly, FSK also induced Oxr1 expression. Thus, FSK-
induced Gh expression is at least partly dependent on OXR1
and is correlated with upregulation of OXR1 in transcription.
To test whether PRMT5 cooperates with OXR1 in Gh regula-
tion, we silencedPrmt5 inOxr1AKOGH3 cells. The data showed
no further significant reduction of Gh expression as compared
with the Oxr1A KO control, suggesting that PRMT5 and OXR1
operate via the same pathway/mechanism for Gh regulation
(Figure S5F). All together, these data strongly suggest that Gh
transcription in the pituitary gland is regulated by OXR1A and
PRMT5.
Transcriptome Analyses of the Pituitary Gland Cell Line
GH3 Show a Role for OXR1A in Regulation of GH and
Signal Transduction
To further examine the role of OXR1A in transcription regulation
in the pituitary, we performed RNA-seq of three biological repli-
cates of OXR1A KO and WT GH3 cell lines. We identified 484
DEGs; of which, 352 genes were downregulated and 132 genes
were upregulated in OXR1A KO GH3 cells in comparison to WT
controls (Figure S5G). RNA-seq showed that Gh gene expres-
sion was significantly downregulated in OXR1A KO cells (Fig-Figure 5. OXR1 Promotes Histone Arginine Methylation In Vivo and In
(A) Western blot analysis of PRMT5 catalyzed histone H3 methylation in WT (WT) a
relative to that of WT cells. H3R2me2s, H3R2 symmetric dimethylation; H3R2me
was used as loading control. n = 3.
(B) ChIP assay with the H3R2me2s or H3 antibody. IgG was used as a negativ
presented as a percentage related to chromatin input. n = 4.
(C) C14 SAM-based H3 methylation assay with PRMT5 or OXR1A. The reactions
(60–240 nM). Control experiments were performed with PRMT5/MEP50 (240 nM
(D) C14 SAM-based H3 methylation assay with PRMT5 and OXR1A together. The
OXR1A (600 nM). Left panel: one representative experiment. Right panel: qua
detectable.
(E) The H3R2me2s-specific antibody was used to detect arginine-specific meth
MEP50 complex (15 nM) and two concentrations of OXR1A (45 and 60 nM). Bot
experiments. n = 6.
(F) Methylation assays with N-terminal H3 peptides as the substrate and PRMT5
DTLDc). WT and twomutant N-terminal H3 peptides (aa 1–21) were used as substr
reactions were supplied with PRMT5/MEP50 complex in presence of [3H] SAM.M
presented from one of two independent quadruplicate assays. Error bars repres
(G) Model of OXR1A function and mechanism of action. OXR1A-PRMT5-depend
promoter activate gene expression. Consequently, depletion of OXR1A results
disease.
Error bars represent mean ± SD. *p < 0.05, **p < 0.01.
See Figure S6.
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Analysis using the KEGG database showed that the top enriched
pathways of the DEGs contained cAMP signaling, focal adhe-
sion, MAPK signaling, and extracellular matrix (ECM)-receptor
interaction, indicating OXR1A has an important role in cellular
signaling transduction via transcription regulation (Table S6).
In addition, GO analysis showed that the cellular components
of the DEGs were enriched in extracellular regions (Table S7),
whereas the molecular functions were mainly enriched in protein
binding, cytokine activity, and ion channel activity (Table S8).
In sum, GH3 RNA-seq supports a role for OXR1A in transcription
regulation in the pituitary gland, including GH expression and
signal transduction.
The C-Terminal TLDc Domain in OXR1A Is Crucial for
Regulation of Gh Expression
To map the functional effect of the core TLDc domain of OXR1A
in transcription regulation of GH, we performed rescue experi-
ments in GH3 OXR1A KO cells by expressing full-length human
OXR1A (hOXR1A) and hOXR1A lacking the C-terminal TLDc
domain (OXR1A DTLDc) (Figure 4F). Both proteins were fused
to GFP in the pEGFP-N vector, showing 30%–40% transfection
efficiency (Figure 4F). Notably, GH expression of bothmRNA and
the protein levels in GH3 OXR1 KO cells were significantly
rescued by full-length hOXR1A but not by the truncated hOXR1A
protein-expressed cells. These results suggest that the C-termi-
nal TLDc domain is crucial for regulation of Gh expression.
Accordingly, expression by the hOXR1A full-length protein
showed significant increase of the H3R2me2s modification in
GH3 KO cells (Figure S5I).
OXR1 Promotes Symmetric Dimethylation of Histone H3
Arginine 2 at the Gh Promoter
PRMT5 is the primary methyltransferase for symmetric dimethy-
lation of arginine in vivo. Of particular importance for transcrip-
tional activation, PRMT5 dimethylates histone H3 arginine 2Vitro
nd Oxr1A/ GH3 cells (Oxr1 Ex3). Methylated H3 in Oxr1A/ was calculated
1, H3R2 monomethylation; H4R3me2s, H4R3 symmetric dimethylation. Actin
e control. Enrichment of promoters of genes was quantified by qPCR and is
were supplied with H3 (22 mM) and increasing concentrations PRMT5/MEP50
) and/or OXR1A (600 nM) without H3 (last lane). H3-me, methylated H3.
reaction was supplied with H3 (22 mM), PRMT5/MEP50 complex (120 nM), and
ntification of H3 methylation from two experiments. n = 6. #Signal was not
ylation on H3 by western blot. The reactions were supplied with the PRMT5/
tom panel: one representative experiment. Top panel: quantification from two
and full-length OXR1A or OXR1A lacking 163 aa at the C-terminal end (OXR1A
ates: H3 (1–21)_WT, H3 (1–21)_R8K/R17K, and H3 (1–21)_R2K/R8K/R17K. The
ethylated peptides were detected by scintillation counting. Representative data
ent SD. *p < 0.05, compared with its relative setting without OXR1A.
ent symmetric dimethylations of histone H3 arginine 2 (H3R2me2s) on the GH
in reduced Gh expression, dysregulation of liver metabolism, and fatty liver
symmetrically (H3R2me2s) to maintain euchromatin (Migliori
et al., 2012). Further, H3R2me2s promotes H3K4 trimethylation
and downstream gene activation (Kirmizis et al., 2007; Yuan
et al., 2012). Therefore, we hypothesized that OXR1A promotes
PRMT5-dependent H3R2me2s and facilitates transcription of
Gh. First, we measured the cellular level of H3R2me2s and other
PRMT5-catalyzed histone modifications in GH3 cells. Western
blot analysis showed that H3R2me2s and H4R3me2s were
reduced 60% and 20%, respectively, in Oxr1A/ cells as
compared with WT cells (Figure 5A). H3R2 monomethylation
(H3R2me1) was not significantly changed in OXR1A-deficient
cells (Figure 5A). Next, we examined enrichment of H3R2me2s
at the Gh promoter by chromatin immunoprecipitation (ChIP)
from Oxr1A/ and WT GH3 cells. Indeed, the Oxr1A/ GH3
cell line showed reduced H3R2me2s binding to the Gh pro-
moters but no reduction of binding toGapdh and Pit1 promoters
as compared withWT cells (Figure 5B). The enrichment of theGh
promoter shown by ChIP with the H3R2me2s antibody in WT
cells was more than 100-fold greater than the ChIP with only
immunoglobulin G (IgG) (Figure 5B), confirming the specificity
of the H3R2me2s antibody. ChIP with the histone H3 antibody
showed the same enrichment of Gh promoters in Oxr1A/
and WT cells, demonstrating that the reduction of H3R2me2s
is not caused by a reduction in histone H3 on the Gh promoters.
In agreement with those results, knockdown ofOxr1 in GH3 cells
by siRNA showed a reduction in enrichment of H3R2me2s at the
Gh promoter (Figure S6E). In sum, these data suggest that OXR1
regulatesGh transcription by promoting PRMT5-catalyzed sym-
metric dimethylation of histone H3R2. Interestingly, Prl, which is
regulated by the same transcription factor as Gh, Pit1, was also
downregulated by knockdown of Oxr1 and Prmt5 as well as by
KO of Oxr1A in GH3 cells (Figure S6B and S6C). ChIP qPCR
suggested OXR1 regulates PRL by a mechanism similar to Gh
regulation by promoting the H3R2me2s at the Prl promoter
(Figure S6D).
Recombinant OXR1A Protein Stimulates PRMT5-
Catalyzed Symmetric Dimethylation of H3R2 In Vitro,
Revealing an Essential Role for the C-Terminal TLDc
Domain
PRMT5 is reported to associate with methylome protein 50
(MEP50), which has an important role in PRMT5 substrate recog-
nition and catalysis. The PRMT5/MEP50 complex catalyzes both
monomethylation and symmetric dimethylation of H3 at R2
(Wang et al., 2014), which is more active than that of PRMT5
alone. Therefore, we used the PRMT5/MEP50 complex in
methylation assays with histone H3 as substrate. We employed
three methods to detect H3 methylation. First, we monitored the
total H3 methylation with 14C S-adenosyl-L-methionine (SAM) as
methyl donor, showing a linear increase in H3 methylation with
increasing concentrations of PRMT5/MEP50 (Figure 5C). Next,
we compared methylation of H3 by PRMT5/MEP50 with or
without OXR1A purified by Ni-NTA and gel filtration columns
(Figure S6F), showing a 1.5-fold increase in H3 methylation in
the presence of OXR1A (Figure 5D). In addition, we showed
that OXR1A was not methylated by the PRMT5/MEP50 complex
(Figure 5C, last lane). These data demonstrated that OXR1A
stimulates PRMT5 activity.Next, we used the histone methylation-specific antibodies to
measure H3R2 monomethylation (H3R2me1) and symmetric
dimethylation (H3R2me2s). The PRMT5/MEP50 complex alone
catalyzed symmetrical dimethylation of H3 at a slow rate (Fig-
ure 5E). Addition of OXR1A to the reaction mixture with
PRMT5/MEP50 stimulated H3R2me2s about 2–3-fold as
compared with PRMT5/MEP50 alone (Figures 5E and S6G).
We also compared symmetric dimethylation versusmonomethy-
lation of H3R2 in parallel with increasing concentrations of
OXR1A, suggesting that H3R2me2s is the major product of
OXR1 stimulation of PRMT5. (Figure S6G). OXR1 itself did not
catalyze H3 dimethylation if the reaction system was lacking
PRMT5/MEP50 (Figure 5E).
PRMT5 can methylate several arginine residues at the H3
N-terminal tails, i.e., R2, R8, and R17. To confirm the specificity
of OXR1A-dependent co-activation of PRMT5-catalyzed H3R2
methylation, we tested PRMT5/MEP50 methyltransferase activ-
ity on WT and mutant peptides of the H3 N-terminal tail (aa 1–21)
as substrates. Further, we addressed the role of the C-terminal
TLDc domain for PRMT5 co-activation with a truncated version
of human OXR1A lacking 163 residues at the C-terminal end
(the entire TLDc domain). Methyltransferase assays with
PRMT5/MEP50 and H3 (1–21) peptides showed a 2-fold in-
crease in activity by addition of the full-length hOXR1A, whereas
OXR1A DTLDc showed no significant increase in activity (Fig-
ure 5F), strongly suggesting that the C-terminal TLDc domain
is essential for co-activation. Control experiments with the H3
(1–21) R2K/R8K/R17K mutant peptide lacking all three R resi-
dues showed no activity, demonstrating that the PRMT5 reac-
tion is arginine specific. Moreover, PRMT5 methyltransferase
assays with the H3 (1–21) R8K/R17K mutant peptide with only
R2 present showed a robust methyltransferase activity, although
stimulation by hOXR1A was less proficient but still significant.
Taken together, these data indicate that OXR1A is a cofactor
for PRMT5/MEP50-mediated symmetric dimethylation at H3R2.
DISCUSSION
The PRMT family targets not only histones but also a number of
other cellular proteins. Thus, PRMT5 has a pivotal role in diverse
processes, such as transcription, replication, repair, RNA
splicing, signaling, cell cycles, differentiation, apoptosis, and
tumorigenesis. We show that OXR1A stimulates PRMT5 activity
in vitro, and depletion of OXR1A reduced H3R2me2s in vivo.
Thus, OXR1A is possibly involved in a wide range of biological
processes via interaction with PRMTs. For example, PRMT5 is
reported to directly methylate tumor suppressor p53, which is
a transcription factor regulating the expression of genes involved
in cell cycle arrest and apoptosis in response to DNA damage
(Jansson et al., 2008). Our previous study showed that siRNA-
mediated OXR1 depletion led to cell cycle arrest in G2/M, and
differential expression in a subset of p53-regulated genes under
oxidative stress (Yang et al., 2015). A recent study demonstrated
that murine OXR1 binds with PRMT1 in vitro using immunopre-
cipitation (Finelli et al., 2015). This interaction is suggested to
promote the relocalization of FUS and Tdp-43 to the nucleus,
avoiding their aggregation in cytoplasm, a characteristic of
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lateral sclerosis. Here, we confirm that OXR1A also interacts with
PRMT1 in both the nucleus and the cytoplasm (Figure S4C),
although the Oxr1A KO did not affect the level of H4R3me2a
(Figure S6H), which is one of the main histone modification sub-
strates of PRMT1. Thus, whereas OXR1A regulates GH in the
pituitary gland through interaction with PRMT5, we may specu-
late that OXR1A could be a coactivator of several members of
the PRMT family, implicating a broader and more general role
for OXR1A in regulating cellular processes in response to stress
via protein arginine methylation.
Functional mapping of the interaction domain by rescue
experiments in vivo and biochemical assays with purified recom-
binant full-length and truncated humanOXR1A proteins, suggest
a crucial role of the C-terminal TLDc domain in GH regulation and
stimulation of PRMT5 activity. Moreover, PLAs verified the phys-
ical interaction between endogenous OXR1 and PRMT5 in both
the cytoplasm and the nucleus in GH3. In addition to abolishing
its role in regulating GH expression in vivo (Figure 4F), the OXR1A
DTLDc mutant showed no stimulation of PRMT5-catalyzed
H3R2me2s in vitro (Figure 5F). Moreover, we have demonstrated
that the OXR1D protein, which basically is composed of the
TLDc domain, is interacting with the PRMT5 complex as well.
Although OXR1A is selectively expressed in the brain,
Oxr1A/mice showed features of liver steatosis with high levels
of triglycerides within the liver. Several lines of indirect evidence
suggest that this was mediated by decreased GH level. First,
transcriptome analyses of the liver showed that several of the
DEGs are enriched in hormone-regulated pathways. Second,
male Oxr1A/ mice display reduced liver expression of Mup
genes, which are pituitary gland hormone-responsive genes.
Third, Oxr1A/ male mice showed markedly attenuated GH
response to fasting. In contrast, no differences were seen in
TSH, FSH, and ACTH levels in blood, and transcriptional levels
of these pituitary-derived hormoneswere not altered inOxr1A/
male mice.
Finally, we have uncovered a molecular function of OXR1A as
a coactivator of PRMT5 that activates gene transcription of Gh
via histone arginine methylation in the pituitary gland (Figure 5G).
As such, OXR1 may provide a new drug target for manipulating
GH levels and preventing metabolic diseases in human.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
In Vivo Experiments
C57BL/6 mice (WT) and C57BL/6 OXR1A knockout mice (Oxr1A /) were bred in-house. The C57BL/6 ES cell clone (IST13330B9)
for Oxr1A knockout was purchased from Texas A&M institute for Genomic Medicine (TIGM). In brief, the ES cells were injected into
Albino C57BL/6 blastocysts, which were transferred to pseudo-pregnant foster mothers tomake chimericmice. F1micewere gener-
ated by breeding male chimeras with C57BL/6 females and F2 homozygous mutant mice were produced by intercrossing F1
homozygous males and females. Genotypes were determined by PCR analysis with DNA samples extracted from mice ears. All
mice (male and female at age up to 24 months) were housed in a climate-controlled environment on a 12h light/dark cycle with
free access to rodent food and water. Animals were housed in accordance with the laws and regulations controlling experimental
procedures in Norway and the European Union’s Directive 86/609/EEC.
METHOD DETAILS
Tissue Preparation
Mice were sacrificed by cervical dislocation. The brain was removed and one hemisphere was harvested separating six different
regions (cortex, cerebellum, pituitary, thalamus, hypothalamus and hippocampus). All tissue samples were stored in RNAlater
(Sigma) at 4C overnight and then snap-frozen at 80C for subsequent analysis including protein extraction and nucleic acid isola-
tion. While the other hemisphere was fixed in buffered, 4% paraformaldehyde (PFA) for paraffin-embedding and
immunohistochemistry.
Nucleic acid isolation and quantification
TotalDNAand totalRNAwere isolated fromsub-regionsof thebrainusing theAllPrepDNA/RNA/ProteinMiniKit (QIAGEN)according to the
manufacturer’s instructions. Nucleic acid quality and concentration were estimated by Epoch Microplate Spectrophotometer (Bio-Tek).
RNA sequencing
The mRNA was separated from total RNA by Oligo(dT) magnetic beads, and cDNA synthesized by reverse transcription with N6
primer. Adaptors were ligated to the sticky 30 end of the cDNA. Two specific primers were used in PCR to amplify the ligation prod-
ucts. Denature the PCR product by heating and the single strand DNA is cyclized by splint oligo and DNA ligase. Performed
sequencing of the prepared library with SE50 instrument by Beijing Genomics Institute (BGI), China. Primary sequencing data
(raw reads) was subjected to quality control (QC) and filtered into clean reads, which were aligned to the reference sequences using
Bowtie2 andmapped to reference mouse genomemm10 using HISAT (Kim et al., 2015). The alignment data was utilized to calculate
distribution of reads on reference genes andmapping ratio. FPKM, short for Fragments Per Kilobase of transcript per Million mapped
reads, was used to calculate the expression level of the gene.
The NOISeqBIO method (Tarazona et al., 2011) was used to screen differentially expressed genes (DEGs) between two groups.
This method models the noise distribution in each group of biological replicates from the actual data, and thus maintains good
True Positive and False Positive rates when comparing to other methods. The DEGs are determined by the default criteria: Fold-
change R 2 and diverge probability (P) R 0.8. Gene Ontology (GO) and KEGG pathway enrichment analysis were performed using
a hypergeometric distribution model with corrected p value % 0.05 as a threshold.
Gene expression by Quantitative Real-Time Polymerase Chain Reaction
Two-steps qPCRmethod was used to determine RNA levels. First, the cDNA was generated from total RNA samples using the High-
capacity cDNA reverse transcription kit from Applied Biosystem. Real-time PCR reactions were prepared using Power SYBR Green
Kit including about 3 ng cDNA in each reaction, and PCR was performed in the StepOnePlusTM Real-Time PCR System (Applied
Biosystem) with the standard cycle conditions: 95C for 10min; 40 cycles at 94C for 15 s and 65C for 30 s. Samples weremeasured
in triplicates. Gapdh and or Actinß were used as internal standard as indicated. The expression level was calculated by the Cycle
Threshold (CT) parameter using the formula: (ProbeCT) (StandardCT) = z; Probeexpr = 2 z. A standard curve was generated to confirm
that the PCR reactions were run in the linear range. See Table S9 for primer information.
Western blot and antibodies
For western blotting, the brain tissues were homogenized by Fast-pre-24 instrument with setting at 5 kR/S for 30 s. Then added RIPA
buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1mM EDTA, 0.1% SDS, 0.5% Sodium deoxycholate, and 1% Triton X-100), andCell Reports 30, 4165–4178.e1–e7, March 24, 2020 e3
homogenized again by Fast-pre-24 as above setting and centrifuged at 13000 RPM15min at 4C. The protein was isolated from sub-
regions of the brain alternatively using the AllPrep DNA/RNA/Protein Mini Kit (QIAGEN) according to the manufacturer’s instructions.
Total protein concentrations of the extracts were determined using a BCA-assay (Pierce, division of Thermo Fisher Scientific, USA).
The soluble protein extracts were separated by 4%–15%SDS-PAGE (4%–15%Mini PROTEAN TGX, BIO-RAD) and transferred on a
PVDFmembrane (Trans-blot Turbo mini Format 0.2 uMPVDF, cat.170-4156 by BIO-RAD) using a BioRad Trans-blot instrument. The
membrane was blocked with 5% milk or 5% fetal bovine serum (FBS) in PBS-T buffer (137mM NaCl, 2.7mM KCl, 4.3mM Na2PO4,
1.4mMKH2PO4, 0.1% Tween-20) overnight at 4
C following incubation with the indicated primary antibody overnight at 4C, washed
3 times with PBS-T buffer. Then the detection antibodies were used. After washing 3 times with PBS-T buffer, the membrane was
incubated with ECL substrate (Supersignal west femto, VWR) and the signal was detected by a BIO-RAD Fluorescent Imager and
analyzed by Image Lab software. The antibodies used were anti-Actin b (AC-15) (1:5000), anti-Growth hormone antibody
(1:2000), anti-GAPDH-HRP (1:5000), anti-Histone H3 antibody (1:1000), anti-Histone H3 (monomethyl R2) antibody (1:300), anti-His-
tone H3R2 Symmetric Dimethyl Polyclonal Antibody (1:1000), Anti-Histone H4 (symmetric di methyl R3) antibody (1:1000), anti-OXR1
Ab1 (1:2000), anti-OXR1 Ab2 (1:1000), anti-PRMT1 (1:1000), anti-PRMT5 (cell signaling #2252, 1:1000), anti-PRMT5 (GT3610,
1:1000), IgG-HRP anti-goat (1:10000), IgG-HRP anti-mouse (1:10000), IgG-HRP anti-rabbit (1:30000).
Proximity ligation assay
Proximity ligation assays (PLAs) were performed on both fixed siRNA transfected GH3 cells and Oxr1A or total Oxr1 knockout GH3
cell lines. GH3 cell lines were grown on glass coverslips, fixed with 4%PFA (added 1Mglycine in the second wash step after fixation),
and permeabilized with 0.1% Triton-X/1X PBS. The PLA was conducted according to the manufacturer’s instructions using the Du-
olink In SituRed Starter Kit Mouse/Rabbit (Cat. No. DUO92101, SIGMA). After blocking for 30min at 37C, the cells were incubated
with OXR1 (1:200) and PRMT5 antibodies (1:200) overnight at 4C. PLA Anti-Rabbit PLUS and Anti-MouseMINUS probes (containing
the secondary antibodies conjugated with oligonucleotides, were added and incubated at 37C for ligation 30 min. Further the fluo-
rescently labeled oligonucleotides resulting in red fluorescence signals were added to the reaction and incubated for amplification at
37C for 100 min in the dark. The slides were mounted with Duolink In Situ Mounting Medium with DAPI (Cat. No. DUO82040,
SIGMA). Microscopy was carried out using a Leica SP8 confocal microscope equipped with3 40 oil immersion lens. The same input
parameters were used throughout all experiments. The number of in situ PLA signals per cell was quantified using the ImageJ soft-
ware (NIH). In situ PLA signals were counted by enhancing point-like signals and defining a true signal as a local intensity maximum
above a background threshold as previously described (Spears et al., 2012).
Primary pituitary cell culture
Anterior pituitary cells of thewild-type andOxr1A/micewere dispersed as described previously (Vakili et al., 2011) with somemod-
ifications. Wild-type and Oxr1A/ mice were euthanized by cervical dislocation and anterior pituitary glands were isolated and
washed gently with calcium-free phosphate buffered saline (PBS) with 0.1% bovine serum albumin (0.1% BSA/PBS) twice, then
chopped in approximately 1 mm3 pieces with a scalpel and washed again. The tissue fragments were treated with 0.5 mL 0.1%
BSA/PBS containing collagenase type I (1 mg/ml, Sigma Aldrich, C0130), pancreatin (0.5 mg/ml, Sigma Aldrich, P7545), hyaluron-
idase (1mg/ml, Sigma Aldrich, H3506), and trypsin inhibitor (0.5mg/ml, Sigma Aldrich, T6522) for 30min at 37Con a shaker. The cell
suspension was collected in a 15 mL tube and added to 2 mL of FBS. The digestion of the tissue fragments was repeated two times.
Digestion was continued by adding 15 units of DNase I (sigma Aldrich, AMPD1) per 5 mL of digested supernatant, with gentle mixing
for 2 min at room temperature. The cell suspension was filtered through a nylon mesh and centrifuged for 5 min at 1200 rpm at room
temperature. Cells were then suspended, plated at 1 3 105 cells/well in 24-well plates with coverslip (VWR ECN631-1577), in
Dulbecco’s Modified Eagle’s Medium (DMEM) including 4.5% glucose (Sigma, D6429) supplemented with 10% (v/v) FBS, antibiotics
(100 UI/ml penicillin, 100 mg/ml streptomycin). The cells were cultured at 37C for 72 h in a humidified atmosphere of 5% CO2. Here-
after, the cells received fresh medium every 48 h.
Plasmids
The cDNA of human OXR1A ORF (NM_001198533) and the truncated variant of OXR1A lacking the TLDc domain (OXR1A DTLDc)
were synthesized by GeneScript, and inserted in expression plasmid pEGFP-N1 between Xho I and BamHI sites. The constructs
pEGFP-N-hOXR1A and pEGFP-N-OXR1A DTLDc consist of exon 1-16 and 1-12, respectively. Similarly, the cDNA of OXR1A and
OXR1A DTLDc were inserted into plasmid pET28b and fused with the Hisx6 Tag between the Nde I and BamHI sites to obtain
pET28b-OXR1A and pET28b-OXR1A DTLDc plasmids. All the plasmids were verified by sequencing. The pEGFP-N-OXR1A and
-OXR1A DTLDc plasmids were transfected into GH3 and U2OS cells by Lipofectamine 3000 Reagent (Thermo Fisher Scientific).
The plasmids of pET28b-OXR1A and -OXR1A DTLDc were transformed into E. coli and further used for purification of recombinant
hOXR1 proteins.
Mass spectrometry for identification of OXR1A interaction partners
The human plasmids pEGFP-N-OXR1A was transfected into the human cell line U2OS to establish cell lines stably expressing
OXR1A-GFP proteins. Cells from T75 flasks were collected and proteins from cell extract were pulled down using a GFP-Trap M
kit (Chromotek). The OXR1 binding proteins were identified and quantified by a MS instrument QExactive with Easy nanoLC (Thermoe4 Cell Reports 30, 4165–4178.e1–e7, March 24, 2020
Scientific). The proteins with average enrichment from triplicate samples larger than 5-fold as compared to control (only expression of
GFP) are considered as OXR1 interaction partners. p value at < 0.01.
Targeted mass spectrometry
Sample preparation for targeted mass spectrometry: After above immunoprecipitation of OXR1 and its partners from U2OS extract,
the GFP-Trap beads were washed and kept in 20 mL of 50 mMNH4HCO3 containing 2 mMDTT. Alkylation was performed by adding
1 mL of a 100 mM iodoacetamide to the beads followed by incubation for 40 min at room temperature in the dark. The reaction was
quenched with 1 mL of 100 mM DTT for 20 min. 0.4 mg Trypsin (Thermo Scientific) was added to the samples following by overnight
incubation at 37C in a shaker. Subsequently, the elution containing the generated tryptic peptides were collected and 0.1% formic
acid was added to a final volume of 40 mL. Finally, 12 mL of each sample were transferred to vials containing 10 fmol of the heavy
standards pool and analyzed by targeted mass spectrometry.
Peptide standards for targeted mass spectrometry: Synthetic peptides containing heavy labeled Lysine (+8) or Arginine (+10) (PE-
Potec SRMGrade 2 Peptides, Thermo scientific) were used for method development and as internal standards for chromatographic
quality control. The synthetic peptides used in this study were in Table S9.
Targeted MS: All parallel reaction monitoring (PRM)-based targeted mass spectrometry methods were designed, analyzed, and
processed using Skyline software version 4.1.0.11714 (MacLean et al., 2010). In silico selection of proteotypic peptides was per-
formed via Skyline using the Homo sapiens reference proteome available at https://www.uniprot.org:443/ to exclude non-unique
peptides. Peptide standards were first analyzed on a Thermo Scientific Q Exactive HF mass spectrometer operating in PRM
mode. This data was imported into skyline and used for the selection of the top ionizing peptides (2+ and 3+ charge states) and
to build a scheduled method with retention time windows of 5 min. The method was then employed for detection and quantification
of corresponding peptides in the samples. The information on retention time and fragmentation pattern of the heavy labeled peptide
standards was used for peptide identification. The instrument parameters described below for sample analysis were adopted for
establishment of the PRM method with standard peptides: Tryptic digests were analyzed on a Q Exactive HF mass spectrometer
operating in PRM mode coupled to an EASY-nLC 1200 UHPLC system (Thermo Scientific). Peptides were injected onto an Acclaim
PepMapC18 column (75 mm i.d.3 2 cmnanoviper, 3 mmparticle size, 100 Å pore size) (ThermoScientific) and further separated on an
EASY SprayTM LC column (75 mm i.d. 3 50 cm nanoviper, 2 mm particle size, 100 Å pore size) (Thermo Scientific) at 40C. The
following 120 min method was used at 300 nl/min flow rate: starting with 6% buffer B (80% Acetonitrile, 0.1% Formic acid) with
an increase to 31% buffer B in 105 min, followed by an increase to 100% Buffer B over 6 min, where it was subsequently held for
9 min. Buffer A consisted of 0.1% Formic acid. The peptides eluting from the column were ionized by an Easy SprayTM Source
(Thermo Scientific) and analyzed on positive-ion mode using electrospray voltage 1.75 kV and HCD fragmentation. Each MS/MS
scan was acquired at a resolution of 60 000 FWHM, normalized collision energy (NCE) 28, automatic gain control (AGC) target value
of 2 3 105, maximum injection time (mIT) of 110 ms and isolation window 1.4 m/z.
Protein Quantification: Heavy labeled peptides were spiked into the samples and used for chromatography quality control and
peptide identification. However, due to the high concentration of internal standards in relation to endogenous peptides, quantification
of endogenous peptides was not based on heavy/light ratios. Instead, quantification of peptides detected in the samples was
achieved by summing the integrated peak areas of the most intense fragments. Peptide areas for multiple peptides of the same pro-
tein were summed to assign relative abundance to that protein. To evaluate the levels of each protein in distinct groups, values of
relative abundance of each protein in samples belonging to the same group were averaged. Each group consists of 3 biological
replicates. A minimum of 2 peptides per protein was used for quantification.
Immunofluorescent staining
The cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in PBS. The cells were subsequently incu-
bated in the presence of blocking buffer containing 5% goat serum, 5% bovine serum albumin and 0.1% Tween 20 in PBS for
30min followed by incubation with primary antibodies diluted in PBS buffer containing 0.5%goat serum, 0.5%bovine serum albumin
and 0.1% Tween 20 at 4C overnight. After three washes in PBS containing 0.1% Tween 20, staining with secondary antibodies was
performed for 60min at room temperature in the dark. After threewashes in PBS containing 0.1%Tween 20 (10min each) and once in
PBS, the slides were mounted with Duolink In Situ Mounting Medium with DAPI (Cat. No. DUO82040, SIGMA). Microscopy was
carried out using a Leica SP8 confocal microscope equipped with 3 40 oil immersion lens. The antibodies used were anti-
PRMT5 (anti-PRMT5, 1:200), anti-Growth hormone antibody (1:200-400), Anti-Rabbit IgG–Cy3 antibody produced in sheep
(1:500), Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (1:500), Alexa Fluor 488 Goat Anti-Rab-
bit IgG (1:500), Alexa Fluor 594 Goat Anti-Mouse IgG (1:500).
Isotope C14 SAM based methylation assay
The assay was performed in a total reaction volume of 15 mL reaction including 1x PBS buffer, 5 mg Histone H3 from calf thymus
(Sigma Aldrich, 11034758001), recombinant PRMT5/MEP50 complex (Active motif, Catalog No: 31356), 5 nmol [14C] SAM (Adenosyl
-L-Methionine, S-[methyl-14C]-, 10mCi (370kBq), Perkin Elmer). Added 1 ml purified OXR1A protein (concentration as indicated) or
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buffer to reactionmixtures, heated at 65C 5min, loaded on a 4%–15%SDS-PAGE, dried the gel on filter paper, exposed the gel on a
low energy storage phosphor screen (GE) for 3 days at RT. Methylated histone H3 was detected by Typhoon imager (GE).
Antibody-based methylation assay
In vitro histone H3mono- and di-methylation assay was also performed using recombinant human histone H3 (Recombinant Histone
H3 (C110A), CatalogNo: 31207, Activemotif). HistoneH3 (1.5 mg) was incubatedwith recombinant PRMT5/MEP50 complex (52.5ng),
and either 1 ml purified OXR1A protein (concentration as indicated) or protein buffer (same as OXR1A dissolved in) in a 30 ml reaction
mixture of PBS buffer containing 0.6 nmol SAM (S-adenosylmethionine, New England Biolabs) for 1 hour at RT. Added 10 ml 4xNu-
PAGE buffer to reaction mixtures, heated at 65C 5 min and loaded on a 4%–15% SDS-PAGE. The following steps were done
according to western blot described above. The mono-methylation at Arg-2 of Histone H3 was detected by anti-Histone H3
(mono methyl R2) antibody (ab15584, abcam, 1:300), and symmetric dimethylation at Arg-2 (H3R2) was detected by anti- Histone
H3R2 Symmetric Dimethyl Polyclonal Antibody (A-3705-100, Epigentek, 1:1000).
Methylation assays with H3 N-terminal tail (aa 1-21) peptides
In vitromethylation assays with 7.35 nM PRMT5/MEP50 complex (Active motif, Catalog No: 31356), 0.4 mMN-terminal H3 peptides
(H3(1-21) WT, H3(1-21)_R8K/R17K or H3(1-21)_R2K/R8K/R17K),with and without OXR1A (29 nM) or truncated OXR1A (29 nM,
OXR1A DTLDc) were carried out in 50 mM HEPES (pH 8.0), 10 mM NaCl, and 1 mM DTT containing [3H] SAM (25:1 molar ratio of
SAM(B9003S, NEB) to [methyl-3H]-SAM (NET155001MC, PerkinElmer). Reactions were incubated for 1 h at 37C, and then
quenched with 0.5 mL of 100% (vol/vol) TFA. Each reaction was run in quadruplicate. Twenty-five microliters of each reaction
were transferred to MilliporeSigma MultiScreenHTS 96-Well Filter Plates with Negatively Charged Membrane (10245703) and air-
dried for 30 min. The papers were subsequently washed in 50 mM NaHCO3 at pH 9.0 for 45 min as previously described (Jain
et al., 2017), and according to the manufacturing introduction. Radioactivity was counted using a 1450MicroBeta Instrument (Wallac
at Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway), as previously described (Faus-
kanger et al., 2018).
Generation of rat OXR1 knockout cell line
The guiding RNA (gRNA) oligos were designed using CRISPR Design Tool (Hsu et al., 2013), gRNAs that target exon 3, 5 and 15,
and with low off target predictions were selected. The oligos (aaacGGGTTCAACCCTTTGGGTGGc, aaacGGGTT
CAACCCTTTGGGTGGc, caccgGTATATTCAATAGTTCCCTT, caccgGTATATTCAATAGTTCCCTT, aaacAAGGGAACTATTGAATA
TACc, caccgGACATGGATTCGTTAGCGTT, aaacAACGCTAACGAATCCATGTCc) were purchased from Sigma, and cloned into
and plasmid pLentiCRISPER V2 according to protocol (Shalem et al., 2014). To make lentiviruses, 2 mg of pLentiCRISPER V2 was
co-transfectedwith 3 mg of Trans-lentivirak packagingMix (TLP4606, Thermo Scientific) into 2x10̂ 6 HEK293T cells (OpenBiosystem)
seeded in 6 well trays, by using X-tremeGENE HP DNA Transfection Reagent (Roche). 24-72 hour after co-transfection, steril-filtered
(40 mm) media from the HEK293T culture was transferred to 12 well trays containing 1x10̂ 5 GH3 cells/well. Infected cells were
selected by using 2 mg/ml Puromycine (Invitrogen) in F12K media supplemented with 20% FCS (Sigma) and 2 mM L-Glutamine
(Sigma). After 7 10 days of selection, cells were sub-cloned and screened by western blot using anti OXR1 antibody (OXR1
Ab1, N106.1).
Mouse GH ELISA assay
Circulating levels of GHwere assayed by ELISA.We fasted 6-month-oldWT andOxr1A /mice, eightmice in each group, for 4 hours
from 7 am. We collected blood samples at30 and 5, 30, and 240 min from Lateral saphenous vein with Microvette tubes (Microv-
etteCB 300 ml, K2 EDTA, violet US code, Sarstedt), 50 ml each time, andmonitored glucose level before and after fasting. The blood
samples were centrifuged at 12,000 rpm for 5 min at 4C, and the plasma samples were collected and stored at 80C. The plasma
GH concentration was measured using commercially available ELISA kit (EZRMGH-45K, Millipore Co) according to the manufac-
turer’s instructions. Absorbance for GH was measured and analyzed using a standard curve. We analyzed the individual provocative
growth hormone response by calculation the ratio of peak and basal level of GH concentrations.
Chromatin immunoprecipitation (CHIP)
For CHIP experiments, the cells were harvested by trypsin digestion and crosslinked using formaldehyde (1% final, Sigma) in normal
culture medium for 10min at room temperature. The cells were washed twice with cold PBS. The cells were lysed and chromatin was
prepared using a Chromatin extraction kit (abcam, Ab117152). The chromatin was sheared to an average size at 250-300 bp using a
Bioruptor Pico (Diagenode) in a 0.65 mL tube for 10 cycles (each cycle was 30 s on and 30 s off). IP was performed using a CHIP kit
Magnetic-One-Step (abcam, ab156907). Briefly, a total of 3-6 mg chromatins were mixed with 1 mg antibody or IgG in CHIP buffer
(total 100 mL per reaction). The mixture was incubated on a rolling shaker for 120 min at 4C. The reaction was washed 4 times
with washing buffer, once by DNA release buffer, and eluted by adding 39 mL DNA release buffer and 1 mL proteinase K. The cross-
links were reversed by incubating the elution sample at 65C 15min and then 95C 10min in a thermal cycler. The input was prepared
by adding 90 ml DNA release buffer in 10 mL chromatin sample following reversal of crosslinks as above.e6 Cell Reports 30, 4165–4178.e1–e7, March 24, 2020
Histological staining in liver tissues
Liver tissue isolated from WT and Oxr1A/ mice was fixed in 4% formalin and embedded in paraffin for histological analysis. Liver
Sections (4 mm) were deparaffinized and stained with hematoxylin (Vector Laboratories Inc.) and eosin (Histolab). Images were
captured by use of a Nikon DS Fi1 camera and a Nikon Eclipse E400 microscope.
Hepatic triglyceride (TG) and cholesterol (CHOL) measurements
Liver lipid extraction was performed and cholesterol and TG levels were quantified by use of enzymatic colorimetric kits (WakoChem-
ical GmbH, Neuss, Germany) according manufacturers protocol.
Activities of murine liver enzymes involved in FA metabolism
The liver enzyme activity was measured by carnitine palmitoyl transferase assay for CPT-1,2, by spectrophotometric assay for FAO
(fatty acyl-CoA oxidase) (Øie et al., 2013).
Oral Glucose Tolerance Test and Blood glucose measurement
Oral glucose tolerance test was performed on bothWT andOxr1A/mice. Mice were fasted for 4 hours; fasted glucose values were
determined and subsequently were given an oral dose of glucose (2mg/kg of body weight). Blood glucose values weremeasured 20,
40, 60, 90 and 120 min after glucose ingestion. Glucose concentrations were measured in venous blood with a glucometer (Accu-
Chek Aviva, Roche, Basel, Switzerland).
QUANTIFICATION AND STATISTICAL ANALYSIS
Each assay consists of at least three independent experiments with technical triplicates except those described specifically. The re-
sults are presented as average values with SD unless otherwise stated. Statistical analysis was performed by calculating p values
using Student’s t test with two tailed distribution between groups assuming equal variances. A confidence level of 95%
(*p < 0.05; ** p < 0.01) was considered statistically significant.
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